Related Experiment Videos
HER-2/neu oncogenic protein: issues in vaccine development
1Division of Oncology, University of Washington, Seattle 98195-6527, USA.
Critical Reviews in Immunology
|January 7, 1998
Summary
New cancer vaccines use defined tumor antigens for precise testing. Understanding immune responses to self tumor antigens is key for effective cancer therapeutics and overcoming tumor immune escape.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer vaccines utilizing whole tumor cells or mixed antigens show promise.
- Advances allow testing of vaccines with well-characterized proteins and peptides.
- Defining human tumor antigens is crucial for next-generation cancer vaccines.
Purpose of the Study:
- To enable precise evaluation of cancer vaccine efficacy.
- To investigate the role of self tumor antigens in cancer immunity.
- To address the challenge of harnessing immunity against self tumor antigens.
Main Methods:
- Testing vaccines composed of known and defined protein and peptide antigens.
- Screening for existent immunity against nonmutated self proteins in human melanoma.
- Investigating immune responses to tumor antigens like MAGE, MART, gp100, and tyrosinase.
Main Results:
- The use of defined antigens allows for more precise determination of vaccine success or failure.
- Human malignancies are immunogenic, with identified human tumor antigens.
- Immunity to self proteins (e.g., MAGE, MART, gp100, tyrosinase) has been observed in melanoma patients.
Conclusions:
- Defined tumor antigen vaccines offer a more accurate approach to cancer vaccine research.
- Self antigen tolerance may be a mechanism for tumor immune escape.
- Harnessing immunity to self tumor antigens presents a significant challenge and opportunity for cancer therapeutics.